CR20140361A - Inhibidores de pde9 con estructura básica de imidazotriazinona - Google Patents

Inhibidores de pde9 con estructura básica de imidazotriazinona

Info

Publication number
CR20140361A
CR20140361A CR20140361A CR20140361A CR20140361A CR 20140361 A CR20140361 A CR 20140361A CR 20140361 A CR20140361 A CR 20140361A CR 20140361 A CR20140361 A CR 20140361A CR 20140361 A CR20140361 A CR 20140361A
Authority
CR
Costa Rica
Prior art keywords
imidazotriazinona
basic structure
pde9 inhibitors
inhibitors
pde9
Prior art date
Application number
CR20140361A
Other languages
English (en)
Inventor
Niels Svenstrup
Klaus Baek Simonsen
Lars Kyhn Rasmussen
Karsten Juhl
Morten Langgard
Kate Wen
Yazhou Wang
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of CR20140361A publication Critical patent/CR20140361A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se refiere a compuestos, que son inhibidores de la enzima PDE9. La invención proporciona una composición farmacéutica que comprende una cantidad terapéuticamente eficaz de un compuesto de la invención y un portador farmacéuticamente aceptable. La presente invención también proporciona procesos para preparar compuestos de fórmula (I).
CR20140361A 2012-01-26 2014-07-24 Inhibidores de pde9 con estructura básica de imidazotriazinona CR20140361A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2012070718 2012-01-26
CN2012080208 2012-08-16
PCT/EP2013/051451 WO2013110768A1 (en) 2012-01-26 2013-01-25 Pde9 inhibitors with imidazo triazinone backbone

Publications (1)

Publication Number Publication Date
CR20140361A true CR20140361A (es) 2014-11-11

Family

ID=47603775

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140361A CR20140361A (es) 2012-01-26 2014-07-24 Inhibidores de pde9 con estructura básica de imidazotriazinona

Country Status (15)

Country Link
US (3) US9434733B2 (es)
EP (2) EP2807163B1 (es)
CN (2) CN107082783B (es)
AP (1) AP2014007820A0 (es)
AU (2) AU2013213603B2 (es)
BR (1) BR112014018199A8 (es)
CO (1) CO7020913A2 (es)
CR (1) CR20140361A (es)
DO (1) DOP2014000175A (es)
EC (1) ECSP14015609A (es)
HK (1) HK1199879A1 (es)
MX (1) MX351582B (es)
PH (1) PH12014501695B1 (es)
SG (1) SG11201403909RA (es)
WO (1) WO2013110768A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR083058A1 (es) 2010-09-20 2013-01-30 Envivo Pharmaceuticals Inc Compuestos de estructura de imidazotriazinona
US9561338B2 (en) 2010-10-08 2017-02-07 Fisher & Paykel Healthcare Limited Breathing assistance apparatus
CA2886885C (en) 2011-10-10 2019-07-16 H. Lundbeck A/S Pde9i with imidazo pyrazinone backbone
EP2807163B1 (en) 2012-01-26 2017-03-22 H. Lundbeck A/S Pde9 inhibitors with imidazo triazinone backbone
EP2828262A4 (en) 2012-03-19 2015-09-23 Forum Pharmaceuticals Inc IMIDAZOTRIAZINONVERBINDUNGEN
WO2016006975A2 (en) * 2014-07-11 2016-01-14 St Pharm Co., Ltd. Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
KR20160007347A (ko) 2014-07-11 2016-01-20 에스티팜 주식회사 신규한 이미다조트리아지논 또는 이미다조피라지논 유도체, 및 이들의 용도
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
WO2017000276A1 (en) * 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclic heterocyclic compounds as pde2 inhibitors
EP4335497A3 (en) 2015-07-07 2024-05-01 H. Lundbeck A/S Pde9 inhibitor with imidazo pyrazinone backbone for treatment of peripheral diseases
CN105669680B (zh) * 2016-03-24 2018-02-23 南京药捷安康生物科技有限公司 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
WO2018009424A1 (en) * 2016-07-06 2018-01-11 Imara, Inc. Pde9 inhibitors for treatment of peripheral diseases
WO2018073251A1 (en) 2016-10-18 2018-04-26 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors
CN109803653A (zh) 2016-10-28 2019-05-24 H.隆德贝克有限公司 包括给予咪唑并吡嗪酮的组合治疗
MX2019004763A (es) 2016-10-28 2019-07-01 H Lundbeck As Tratamientos de combinacion que comprenden imidazopirazinonas para el tratamiento de trastornos psiquiatricos y/o cognitivos.
WO2018091687A1 (en) * 2016-11-18 2018-05-24 Integrative Research Laboratories Sweden Ab Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
CN110325193B (zh) * 2017-02-23 2023-05-05 勃林格殷格翰国际有限公司 化合物iii的新型医学用途
DK3630772T3 (da) * 2017-05-26 2024-02-05 Cardurion Pharmaceuticals Inc Fremgangsmåder til fremstilling og anvendelse af pde9-hæmmere
CN110003213B (zh) * 2018-01-04 2021-10-08 南京农业大学 苯并咪唑并三嗪酮类化合物、制备方法及应用
KR20200106513A (ko) 2018-01-05 2020-09-14 다이서나 파마수이티컬, 인크. 면역요법을 강화시키기 위하여 베타-카테닌 및 ido 발현의 감소
WO2020227399A1 (en) * 2019-05-07 2020-11-12 Imara Inc. Pde9 inhibitors for treating thalassemia
CN113072556B (zh) * 2021-03-30 2022-02-01 牡丹江医学院 一种用于治疗胶质瘤的药物及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2346877B (en) 1997-11-12 2001-12-05 Bayer Ag 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
EE200100377A (et) 1999-01-20 2002-10-15 Arzneimittelwerk Dresden Gmbh Imidaso[1,5-a]-pürido[3,2-e]-pürasinoonide kasutamine arstimitena
PL370599A1 (en) * 2001-11-02 2005-05-30 Pfizer Products Inc. Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
HN2002000317A (es) 2001-11-02 2003-05-21 Pfizer Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
GB2388111A (en) 2002-05-01 2003-11-05 Bayer Ag Novel imidazotriazinone compounds
US6684626B1 (en) 2002-07-30 2004-02-03 General Electric Company Aircraft gas turbine engine with control vanes for counter rotating low pressure turbines
US20040220186A1 (en) * 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
WO2005041972A1 (en) 2003-10-31 2005-05-12 Pfizer Products Inc. Phosphodiesterase 9 inhibition as treatment for obesity-related conditions
AR053090A1 (es) 2004-07-20 2007-04-25 Osi Pharm Inc Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
TW200815436A (en) 2006-05-30 2008-04-01 Elbion Ag 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
ES2599054T3 (es) 2006-12-13 2017-01-31 Aska Pharmaceutical Co., Ltd. Derivados de quinoxalina
ATE540954T1 (de) 2007-05-11 2012-01-15 Pfizer Aminoheterocyclische verbindungen
DE102007032349A1 (de) 2007-07-11 2009-01-15 Bayer Healthcare Ag Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung
CN102015684A (zh) 2007-12-10 2011-04-13 葛兰素集团有限公司 联-吡啶基吡啶酮作为黑色素浓缩激素受体1拮抗剂
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
WO2011011712A1 (en) 2009-07-24 2011-01-27 Concert Pharmaceuticals, Inc. Substituted imidazotriazines
WO2011028820A1 (en) 2009-09-02 2011-03-10 Concert Pharmaceuticals, Inc. Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds
AR083058A1 (es) * 2010-09-20 2013-01-30 Envivo Pharmaceuticals Inc Compuestos de estructura de imidazotriazinona
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
EP2807163B1 (en) 2012-01-26 2017-03-22 H. Lundbeck A/S Pde9 inhibitors with imidazo triazinone backbone

Also Published As

Publication number Publication date
PH12014501695A1 (en) 2014-10-20
MX2014008912A (es) 2014-08-26
AP2014007820A0 (en) 2014-07-31
CN107082783B (zh) 2019-03-22
CN104093720B (zh) 2017-04-12
AU2013213603B2 (en) 2017-02-02
CN107082783A (zh) 2017-08-22
EP3178820B1 (en) 2017-12-20
AU2013213603A1 (en) 2014-07-24
BR112014018199A8 (pt) 2021-03-02
CN104093720A (zh) 2014-10-08
CO7020913A2 (es) 2014-08-11
US20170081333A1 (en) 2017-03-23
EP2807163B1 (en) 2017-03-22
EP3178820A1 (en) 2017-06-14
US20160213674A1 (en) 2016-07-28
US9533992B2 (en) 2017-01-03
EP2807163A1 (en) 2014-12-03
US9434733B2 (en) 2016-09-06
ECSP14015609A (es) 2015-12-31
WO2013110768A1 (en) 2013-08-01
AU2017200886A1 (en) 2017-03-02
SG11201403909RA (en) 2014-10-30
MX351582B (es) 2017-10-20
US9850249B2 (en) 2017-12-26
PH12014501695B1 (en) 2014-10-20
DOP2014000175A (es) 2014-08-31
HK1199879A1 (en) 2015-07-24
AU2017200886B2 (en) 2018-01-18
US20150045348A1 (en) 2015-02-12

Similar Documents

Publication Publication Date Title
CR20140361A (es) Inhibidores de pde9 con estructura básica de imidazotriazinona
CR20120317A (es) Derivados de 2-arimidazol heteroaromáticos como inhibidores de enzima pde10a
EA201491362A1 (ru) Анестезирующие соединения и способы их применения
PH12015500260A1 (en) Neprilysin inhibitors
MY165087A (en) Neprilysin inhibitors
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
CO6430501A2 (es) Nuevos compuestos eficaces como inhibidores de la xantina-oxidasa, método para la preparación de los mismos y composición farmacéutica que los contiene
PH12014502733A1 (en) Neprilysin inhibitors
CR20120319A (es) Derivados de fenilimidazol heteroaromáticos como inhibidores de enzima pde10a
CR20140071A (es) Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa
EA201690473A1 (ru) Комбинированный состав двух противовирусных соединений
MD20140136A2 (ro) Inhibitori ai virusului hepatic C
IN2015DN00185A (es)
MY170935A (en) Neprilysin inhibitors
MX354476B (es) Inhibidores de neprilisina.
WO2013003298A3 (en) Inhibitors of pde10
CR20120318A (es) Derivados de aril triazol heteroaromáticos como inhibidores de enzima pde10a
MX2016000675A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos.
ECSP14013239A (es) Composiciones farmacéuticas
ECSP13012698A (es) Derivados de imidazol como inhibidores de la enzima pde10a
BR112012019866A8 (pt) Composto, uso do mesmo, composição farmacêutica, e, processo para preparar um composto
MX2013009386A (es) Nuevos compuestos de azaespirodecanona.
MX2013002656A (es) Nuevo proceso.
TR201009166A2 (tr) Sefdinir içeren farmasötik bileşim için üretim yöntemi
TR201010859A2 (tr) Sefdinir içeren tablet formları.